Severity: Warning
Message: Trying to access array offset on value of type null
Filename: views/press_details.php
Line Number: 14
Backtrace:
File: /home/reportsweb/public_html/application/views/press_details.php
Line: 14
Function: _error_handler
File: /home/reportsweb/public_html/application/controllers/Press_controller.php
Line: 112
Function: view
File: /home/reportsweb/public_html/index.php
Line: 316
Function: require_once
HPV Testing Segment by Type to Hold Largest Share of Cervical Cancer Diagnostic Testing Market During 2021–2028
According to our latest study on “Cervical Cancer Diagnostic Testing Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type and Service Provider,” the market is projected to reach US$ 7,165.92 million by 2028 from US$ 5,141.25 million in 2021; it is expected to grow at a CAGR of 4.9% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.
Cancer has emerged as a leading cause of death across the world. According to the World Health Organization (WHO), cancer was the first leading cause of death in the people of below 70 years in 183 countries and fourth leading cause of death in 123 countries worldwide in 2019. In addition, according to data published by the WHO in March 2021, ~10 million deaths occurred in 2020 due to different cancer types. The rising incidence of cervical cancer among women worldwide drives the cervical cancer diagnostic testing market growth. According to the WHO, more than 270,000 deaths of women are recorded due to cervical cancer each year. Cervical cancer mortality rates are greater in low-income countries due to the late diagnosis of the disease. The market is predicted to grow in the coming years due to the increasing acceptance of cervical cancer diagnostic tests for the early detection of the disease.
Based on type, the cervical cancer diagnostic testing market is segmented into PAP testing, HPV testing, colposcopy, cervical biopsies, cystoscopy, and others. In 2021, the PAP testing segment held the largest share of the market. However, the HPV testing segment is expected to register the highest CAGR in the market during 2021–2028.
F. Hoffmann-La Roche Ltd.; Abbott; Quest Diagnostics Incorporated; QIAGEN; Hologic, Inc.; DYSIS Medical Inc.; Femasys Inc.; Guided Therapeutics, Inc; Cooper Companies, Inc.; and BD are among the leading companies operating in the cervical cancer diagnostic testing market.
Cervical Cancer Diagnostic Testing Market Share, by Region, 2021 (%)
Source: The Insight Partners Analysis
Report Segments Cervical Cancer Diagnostic Testing Market as Follows:
The cervical cancer diagnostic testing market is bifurcated on the basis of type and service provider. Based on type, the market is segmented into PAP testing, HPV testing, colposcopy, cervical biopsies, cystoscopy, and others. Based on service provider, the cervical cancer diagnostic testing market is segmented into diagnostics and research laboratories, hospitals and clinics, specialty clinics, and home care services.
In terms of geography, the cervical cancer diagnostic testing market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, Italy, the UK, Spain, and Rest of Europe), Asia Pacific (Australia, China, India, Japan, South Korea, and Rest of APAC), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and Rest of MEA), and South and Central America (Brazil, Argentina, and Rest of SCAM)